Work for Antibe Therapeutics Inc.?

Claim Your Profile

Antibe Therapeutics Inc. Logo Image

Antibe Therapeutics Inc.

Antibe Therapeutics Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report

Antibe Therapeutics Inc.

Antibe Therapeutics Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

  • Antibe Therapeutics Inc.

About Antibe Therapeutics Inc.

11-50 Employees
Based in Toronto, Ontario

Antibe Therapeutics is a publicly traded biotechnology company pursuing a breakthrough advance in the treatment of inflammation. Their drug pipeline addresses major markets in non-addictive management of chronic and post-surgical pain. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety in the treatment of chronic pain, a condition that affects more than 50 million Americans alone. Their second pipeline drug is intended to replace a range of opioids, addressing a vast and pressing public health concern. Their third drug is a safer daily aspirin -- delivering anti-stroke and anti-cancer benefits without damage to the digestive tract.

Ticker:
ATE
Exchange:
TSX-V (See More TSX-V Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol